|Written by Rob Goldman|
IGNORE THE PRESENT
I hate “last year’s” financial results. And you should too. One of my pet peeves is when analysts or the talking heads refer to valuation by exclusively citing last year’s EPS results. It is borderline meaningless in the grand scheme of things. With the exception of value or specialty investors, shareholders buy stocks based on projected, future results—not how companies executed months (or ages) ago.
We talk a lot about the keys to successful investing. For all the tips and strategies, success can be boiled down to a prescient quote by famed economist John Maynard Keynes:
“Successful investing is anticipating the anticipations of others.”
Anticipating others anticipation is the hallmark of looking ahead. Frankly, if you focus only on the past, you will be disappointed. If you focus only on the present, you will be left behind. If you focus on the future, you can move ahead of the crowd.
That is why our approach is to look ahead before most investors, even at the risk of being early. One needs to prepare the next move based on potential contingencies or eventualities, while simultaneously evaluating the present.
With that in mind, it should be clear to even the most causal investor that we are currently in a directionless market.
A week ago, we noted that the big moves in stocks were narrow but we thought that health care and biotech might give us one last hurrah. Instead, the group sold off pretty strongly (aided by a poor Biogen outlook). Plus, future Apple (NASDAQ—AAPL) growth concerns, along with some Asia slowing has spooked investors in the big caps. So what does this all mean now? Let’s review and forecast...
“Today”, Small Stocks Stink...
Last week’s trading direction and activity ended on a real downer. For the week, the major indices dropped by over 2% while the Russell 2000 Index was slammed by more than 3%. And we haven’t even really started earnings season yet. Yuck.
As ugly as the overall market looks, despite their declining valuations (19x forward twelve month EPS versus 19.7x for the NASDAQ 100), small caps look like total crap—today. But, that is no cause for alarm.
According to Factset Research, Q2 earnings for the most part have tracked a bit better than expected. While some comparisons to the corresponding quarter are negative we are getting closer and closer to very favorable quarterly comparisons. As noted by the chart below, there could be more pain ahead in the short term as we are getting dangerously close to breaking below the 200 DMA of 1213. The Index is essentially at a 4 week low, and it seems inevitable it will hit a 13 week low of 1221, or 6.6% from the year high, before bouncing.
...and so do large ones, but...
If it feels like things turned so far so fast, you are right. The Russell 2000 Index has dropped by 5.4% since reaching a new high about a month ago. And that is just part of the story. It actually looks like the megacaps are just as hurt. Goes to show again that any rallies are narrowly based. The first table illustrates how few stocks are above their short term DMAs while the second lists new highs and lows.
...tomorrow they will do well
There is no reason to fear or be surprised if we come close to or reach the dreaded 10% correction figure. Hell, we are more than halfway there anyway. Semis are soft (down 50% in a month), energy earnings are terrible until early 2015, and biotech, which has roared this year, is starting to crack.
To be fair, right now we are in the midst of mini-market swings with only a modicum of volatility in stocks as they have traded in a narrow range nearly the entire year. As a result, investors concerned over growth or valuation are rooting for declines. Investors seeking to turn a fast buck via sizable shifts in price are rooting for volatility. A majority, however, are likely worried about Fed interest rate increases and global growth.
If a correction occurs for any reason, we believe that the eventual comeback could be with a vengeance based on valuation and earnings growth, and arrive with volatility.
Take comfort in what we believe lies ahead:
In a nutshell, if we have short term swings and volatility until November, don’t sweat it. There will be plenty of opportunities to make money.
This week, we have a combo of news on two key sectors, along with very topical news items.NY Times
This is either brilliant or total bullshit. Read it and decide for yourself.
The Washington Post
Kudos to the Post for being ahead of the game business-wise, for a change.
This is not news but is vital. The real takeaway is that 2016 could be a big earnings growth year as comparisons will be easy in energy and some stocks that faltered in other sectors are expected to do well.
Investor's Business Daily
A little late but many believe this could be the next new tech segment to boom ahead.
This really is an “uh-oh” kind of news story.
Just the Stats!
AAII Sentiment Survey (courtesy of AAII.com, figures rounded)
Modest and mixed changes in the AAII survey shows us one again how confused the market and investors are at present. Notice similar changes and uncertainty in the blogger poll as well. And that is ok! These are lagging indicators but can give us a glimpse of what’s ahead.
Plays of the Week
Just a reminder that Skechers USA (NYSE—SKX—$123.01 –NR), one of our big winners, reports on Wednesday. As we noted last week, we would be sellers on the news due merely to valuation. The Street is looking for $1.01 versus $0.68 and they could surprise on the upside. We are still fans but there comes a time when upside becomes limited.
Orbotech (NASDAQ—ORBK—$18.02—NR), was a big winner earlier this year but has sold off with the semi sector of late. If you are willing to hold on to the stock for 4-6 months, one could see 50% gains. The Company reports 2Q15 results on Thursday and the Street expects $0.51 in EPS versus $0.20. Even if they meet just forecasts and reiterate guidance, ORBK will move. The stock trades less than 10x 2015 EPS of $1.99, despite it is more than double the EPS from last year. It is surely worth $25.
Got the back-to-school bug? It is becoming harder and harder each year to find the best BTS plays, but there is one compelling play out there in the apparel sector. American Eagle Outfitters (NYSE—AEO—$17.53—NR). The stock actually trades above its major DMAs and EPS for the most recently completed quarter is $0.14 versus $0.03, and $0.97 for the year as compared with $0.63. EPS forecasts are on the rise and there have been some upside surprises of late.
AEO is a leading global specialty retailer offering high-quality, on-trend clothing, accessories and personal care products at affordable prices. The company operates more than 1,000 stores in the United States, Canada, Mexico, China, Hong Kong and the United Kingdom, and ships to 81 countries worldwide through its websites. American Eagle Outfitters and Aerie merchandise also is available at 115 international stores operated by licensees in 19 countries.
A good BTS season and solid August financials reporting could mean a 20%+ gain.
Have a good week!
1498 Reisterstown Road, Suite 286 Baltimore Maryland 21208 Phone: 410.609.7100
Launched in May 2010, The Goldman Guide is a free weekly publication of Goldman Small Cap Research and is written by Founder Rob Goldman with contributions from the GSCR contributor team. This non-sponsored investment newsletter seeks to provide investors with market, economic, political and equity-specific insights via an action-oriented, straight to the point approach. No companies mentioned in this newsletter are current sponsored research clients of the Company or its parent, unless noted, With some exceptions, all companies or investment ideas mentioned in this publication are publicly traded stocks listed either on the NYSE or the NASDAQ. Goldman Small Cap Research members and contributors’ bios, certifications, and experience can be found on our website: www.goldmanresearch.com
This newsletter was prepared for informational purposes only. Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces non-sponsored and sponsored (paid) investment research. Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
The Firm’s non-sponsored research publications category, Select Research, reflects the Firm’s internally generated stock ideas, along with economic, industry and market outlooks. In virtually all cases, stocks mentioned in Select Research offerings are listed on the NYSE or the NASDAQ. Publications in this category include the weekly newsletter The Goldman Guide, Market Monitor blogs, Special Reports, and premium products such as The 30-30 Report. Goldman Small Cap Research analysts are neither long nor short stocks mentioned in this newsletter.
Opportunity Research reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored microcap research ideas that typically carry greater risks than those stocks covered in Select Research category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in company-specific Opportunity Research reports, updates and articles.
Goldman Small Cap Research has not been compensated for any content in this issue.
All information contained in this newsletter and in our reports were provided by the companies mentioned via news releases, filings, and their websites or generated from our own due diligence. Economic, market data and charts are provided by a variety of sources and are cited upon publication. Stock performance data and information are derived from Yahoo! Finance and other websites or sources, as noted. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, other firms, or other financial news outlets. Goldman Small Cap Research relied solely upon information provided by companies through filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, blog, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This newsletter does not take into account the investment objectives, financial situation, or particular needs of any particular person. This newsletter does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with the FINRA or with any state securities regulatory authority. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.
Separate from the factual content of our articles about the company featured in this newsletter, we may from time to time include our own opinions about the companies profiled herein, their businesses, markets and opportunities. Any opinions we may offer about the companies are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Such information and the opinions expressed are subject to change without notice.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com.